Interim information January - September 2016.

The full Interim information in pdf is available on Brighter's website www.brighter.se. A pdf copy is also attached to this press release.

January 1 – September 30, 2016. 

• Operating income amounted to SEK 17,073 thousand (SEK 9,276 thousand).
• Profit after financial items amounted to SEK -9,908 thousand (SEK -6,435 thousand).
• Earnings per share before dilution SEK -0.22 (SEK -0.24).
• Earnings per share after dilution SEK -0.22 (SEK -0.24).

Significant events July to September 2016.

• 2016-08-26 – Brighter in final negotiations with mobile operators in Thailand and Indonesia.
• 2016-07-19 – Brighter’s new share issue to repay its loans has now been registered.
• 2016-07-19 – Brighter’s non-cash issue to acquire the company behind jDome® BikeAround™ has now been registered.
• 2016-07-07 – Brighter and Sanmina start working together to produce Actiste®.
• 2016-07-01 – Brighter and Telia sign an agreement for subscription services for the diabetes solution Actiste.

Significant events after the period. 

• 2016-10-25 – Brighter merges its jDome business with Bestic® and plans a public listing as an independent company.
• 2016-10-12 – The Swedish Patent and Registration Office increases Brighter’s patent protection.
• 2016-10-12 – Brighter wins arbitration case against former development partner.
• 2016-10-11 – Brighter carries out a private placement for SEK 11.2 million.
• 2016-10-04 – Brighter receives a breakthrough order for jDome BikeAround in Denmark.

A message from the CEO.

We are extremely happy with the third quarter of this year, as so many important events took place for Brighter. We have taken a major step forward into the production phase, laying a strong foundation for new and exciting partnerships in the future. We are particularly happy about finally having our first operator agreement in place; Telia is a company that has promoted digitalization in society for many years, and the company clearly shares our vision and ideas about how care will develop in the future. Starting to work with Telia marks an important milestone for Brighter. It means that we have a strong partner for the Swedish launch of Actiste in the second half of 2017. This is something we are now planning together.

Ericsson is already one of our strategic partners. In this quarter we worked together on a number of activities to develop our business; this included presenting Actiste at Ericsson’s Digital Forum in Jakarta in the late summer. As one of our partners, Ericsson has also been involved in our ongoing negotiations for new potential collaborations.

Early in the quarter we were able to announce that Brighter had signed an agreement with Sanmina for the production of Actiste. The main reasons why we chose to work with Sanmina include the company’s extensive experience of producing advanced medical devices, including devices for the diabetes segment, and their ISO 13485 certification. Sanmina’s production capacity is also extremely flexible, which enables us to quickly scale up our process to handle some of the production locally on other markets if necessary and to exploit any synergies.

Our main focus over the past quarter has been to negotiate agreements with mobile operators in Indonesia and Thailand. Since November 2015, when we launched our Asian campaign, we’ve learned that it takes time to build relationships and business in the region and we are very proud to have been able to get this far in only one year. Our partnership with Ericsson is off course a key success factor and we expect to sign at least one agreement by the end of this year.

Thailand and Indonesia are two important markets that clearly need better diabetes care; the number of diabetics in Indonesia and Thailand is around 10 million and 4 million respectively; there is also an extremely high growth rate for the disease in the region. In Indonesia the number of diabetics has increased by around 6% annually, which can be compared with around 1% in Sweden. However, what is most striking is the fact that diabetes is growing in every part of the world. There has never been a greater need for or interest in better solutions.

What makes Thailand and Indonesia particularly interesting from a marketing point of view is the fact that these countries are implementing different kinds of national health plans, subsidies and insurance systems. This means that most people can receive care or are able to manage their disease effectively. There is also an ambition to introduce a harmonized regulatory system for medtech products throughout the region through the cooperation organization ASEAN (Association of Southeast Asian Nations). In the future this will make it easier for us to continue to expand and spread Actiste in Southeast Asia.

Finally, I would like to introduce the new company Camanio Care, which is a merger of our activity tool jDome BikeAround and the robotics company Bestic. We merged these businesses in October, which has created a larger and stronger specialist company with a future focus. Although Brighter is a major owner of the company, we will not play an operational role in the business. Instead we are going to focus completely on launching Actiste for the diabetes market, while exploring new potential application areas where this product and our IP portfolio can create extra value.

For more informatin, please contact:

Truls Sjöstedt, CEO
Tel: +46 709 73 46 00
Email: truls.sjostedt@brighter.se 

Henrik Norström, COO
Tel: +46 733 40 30 45
Email: henrik.norstrom@brighter.se

About Brighter AB (publ)

Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care and care for the elderly, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.

The Company's shares are listed on NASDAQOMX FIRST NORTH/BRIG. Brighter's Certified Adviser is Remium Nordic AB, +46 (0)8 454 32 50,  CorporateFinance@remium.com ,   www.remium.com .

This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on November 25 2016. 

Tags: